D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

Eligibility Criteria

• 1. Subjects undergoing an elective colorectal surgery involving resection, with or without a stoma formation, that includes at least 1 abdominal incision that is \>20cm (target incision).
• 2. Subjects are preoperative hemodynamically stable. (BP≤180/110 and \>90/60 mmHg, and HR≤120 and \>60 bpm, and temperature ≤37.50C and \>35.50C).
• 3. Male or non-pregnant female.
• 4. Female of child-bearing potential should have a negative pregnancy test (serum or urine dipstick) prior to index procedure.
• 5. Subjects' age 18 years old and above at screening.
• 6. Subjects who sign the written Informed Consent Form.
• 7. Subjects who are willing and able to participate and meet all study requirements.
• 8. Survival expectancy of at least 60 days post randomization.
• 1. Subjects with suspected/diagnosed intestinal perforation, intra-abdominal abscess, or any emergency/urgent colorectal surgery with acute intestinal obstruction (ex. toxic colitis, ileus/sub-ileus, megacolon, diverticulitis, volvulus, etc.)
• 2. Subjects who underwent an intra-abdominal surgery within the last 6 months prior to randomization.
• 3. Subjects with any preoperative active infection or who are receiving any antibiotic therapy in the past 1 week prior to randomization, excluding pre-operative prophylaxis.
• 4. Subjects undergoing concomitant major procedures in addition to the colorectal resection.
• 5. Subjects who received any anti-cancer treatment within the last 4 weeks of surgery.
• 6. Subjects who received radiation for colorectal cancer to the abdomen and/or pelvis area, prior to the planned abdominal surgery.
• 7. Subjects who received oral or IV Doxycycline or Tetracycline family antibiotics during the past 4 weeks prior to randomization.
• 8. Subjects with known allergy to Doxycycline and/or to the tetracycline family of drugs or to the D-PLEX's excipients.
• 9. Subjects with known allergies to more than 3 substances (an allergy questionnaire will be completed during the screening process).
• 10. Subjects with history of severe allergic reaction to any substance, having required treatment with intravenous steroids/intramuscular epinephrine, or who in the opinion of the PI is at high risk of developing severe allergic reactions.
• 11. Subjects with End Stage Renal Disease (ESRD/ CKD stage 5).
• 12. Subjects with severe hepatic impairment.
• 13. Subjects with chronic urticaria.
• 14. Subjects diagnosed with CVA within the past 6 months prior to randomization.
• 15. Subjects who underwent any abdominal surgery and current planned index surgery involves re-opening the scar of a prior abdominal surgery performed within the last 3 years.
• 16. Any subject with an active malignancy or with malignancy that has not been in complete clinical remission and without maintenance chemo or immunotherapy for at least 3 years.
• 17. Subjects with other concurrent severe and/or uncontrolled medical condition.
• 18. Psychiatric or any other disorder that compromises ability to provide informed consent for participation in this study.
• 19. Chronic alcoholic or drug abuse subjects.
• 20. Pregnant or breast-feeding women or women of child-bearing age who refuse or are prohibited of using an effective contraceptive method of birth control throughout study participation, including the safety follow-up period.
• 21. Subjects who received any investigational drug within 30 days or 5 half-lives prior to randomization to the study (whichever is longer) and through the study.
• 22. Subjects participating in any other interventional study.
• 23. Subjects who in the opinion of Investigator, are not eligible to participate in the study and/or to comply with the protocol requirements (e.g. due to a cognitive or medical condition).